French Innovative Leukemia Organization — Sponsor Intelligence | 9 EU Trials

Filter these 9 trials by condition, phase, country and more.

Open in Search →

9 Registered trials

3 Recruiting

4 Completed trials

1 Countries active

14 Unique IMPs

100% Results reported

Phase II

Phase II: 9

100%

4 of 4 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Acute myeloid leukaemia 3 Waldenstrom's macroglobulinaemia 1 Richter's syndrome 1 Blastic plasmacytoid dendritic cell neoplasia 1

Top IMPs

AZACITIDINE 2 ACALABRUTINIB 1 CYCLOPHOSPHAMIDE 1 DOXORUBICIN HYDROCHLORIDE 1 GILTERITINIB 1 GLOFITAMAB 1 IVOSIDENIB 1 OBINUTUZUMAB 1 PREDNISONE 1 RITUXIMAB 1 TAGRAXOFUSP 1 VENETOCLAX 1

All trials

9 total

Study PACIFIC: Fixed duration treatment with combined pirtobrutinib and short course immuno-chemotherapy in fit patients with previously unt… Pending

2025-521199-80-00 Phase II 1 country
FILO-AML-01-MIVONU A single arm phase II study investigating the efficacy and safety of the addition of ivosidenib to oral azacitidine (Onur… Pending

2025-521322-14-00 Phase II 1 country AZACITIDINE; IVOSIDENIB
FILOWM4-WaZaBi: "Open label phase 2 study evaluating the efficacy and tolerance of a zanubrutinib and BGB-11417 combination in patients prev… Recruiting

2023-505781-28-00 Phase II 1 country
Open label phase II study evaluating the efficacy and safety of the combination of tagraxofusp and venetoclax in treatment-naive blastic pla… Recruiting

2024-511003-42-00 Phase II 1 country TAGRAXOFUSP; VENETOCLAX
FILOCLL015 - GLORIFY - A phase 2 study evaluating the bispecific CD3xCD20 antibody GLOfitamab in combination with rituximab or obinutuzumab … Recruiting

2022-501554-11-00 Phase II 1 country CYCLOPHOSPHAMIDE; DOXORUBICIN HYDROCHLORIDE; GLOFITAMAB; OBINUTUZUMAB; PREDNISON…
PREVENE : Preemptive therapy with Venetoclax for high risk CLL stage A patients, a phase II trial of the FILO Ended

2024-513718-37-00 Phase II 1 country
FILOAML-RR-01-OGILAR: Open-label, phase 2 study investigating the efficacy and safety of the addition of oral-azacitidine to salvage treatme… Ended

2022-501372-25-00 Phase II 1 country AZACITIDINE; GILTERITINIB
FILOCLL14 - STAIR : "Open-label, phase 2 study investigating the STop and restart Acalabrutinib In fRrail patients with previously untreated… Ended

2024-513936-80-00 Phase II 1 country ACALABRUTINIB
LAMSA2020: “A phase II randomized study to assess the efficacy on outcome of Venetoclax combined with Cytarabine versus Idarubicin combined… Ended

2022-502392-37-00 Phase II 1 country

Showing 1–9 of 9 trials

← All sponsors A–Z